Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
…, JC Marshall, FB Mayr, D McAuley, A McGlothlin… - Medrxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Minimal clinically important difference: defining what really matters to patients
AE McGlothlin, RJ Lewis - Jama, 2014 - jamanetwork.com
When assessing the clinical utility of therapies intended to improve subjective outcomes, the
amount of improvement that is important to patients must be determined. 1 The smallest …
amount of improvement that is important to patients must be determined. 1 The smallest …
Trial of early minimally invasive removal of intracerebral hemorrhage
…, JW Allen, G Paulon, A McGlothlin… - … England Journal of …, 2024 - Mass Medical Soc
Background Trials of surgical evacuation of supratentorial intracerebral hemorrhages have
generally shown no functional benefit. Whether early minimally invasive surgical removal …
generally shown no functional benefit. Whether early minimally invasive surgical removal …
Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis
…, M Quintana, M Foster, M Olinger, A McGlothlin… - JAMA …, 2016 - jamanetwork.com
Importance The expense and lengthy follow-up periods for randomized clinical trials (RCTs)
of adjuvant systemic therapy in breast cancer make them impractical and even impossible to …
of adjuvant systemic therapy in breast cancer make them impractical and even impossible to …
The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. Rationale and design
…, E Litton, J Marshall, A McGlothlin… - Annals of the …, 2020 - atsjournals.org
There is broad interest in improved methods to generate robust evidence regarding best
practice, especially in settings where patient conditions are heterogenous and require multiple …
practice, especially in settings where patient conditions are heterogenous and require multiple …
Effect of P2Y12 inhibitors on survival free of organ support among non–critically ill hospitalized patients with COVID-19: a randomized clinical trial
…, C Daelemans, L Paraz, MA Detry, A McGlothlin… - Jama, 2022 - jamanetwork.com
Importance Platelets represent a potential therapeutic target for improved clinical outcomes
in patients with COVID-19. Objective To evaluate the benefits and risks of adding a P2Y12 …
in patients with COVID-19. Objective To evaluate the benefits and risks of adding a P2Y12 …
Effect of vitamin C, thiamine, and hydrocortisone on ventilator-and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial
…, RJ Lewis, CJ Lindsell, JS Marlin, A McGlothlin… - Jama, 2021 - jamanetwork.com
Importance Sepsis is a common syndrome with substantial morbidity and mortality. A combination
of vitamin C, thiamine, and corticosteroids has been proposed as a potential treatment …
of vitamin C, thiamine, and corticosteroids has been proposed as a potential treatment …
[HTML][HTML] Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
…, S Malakouti, DF McAuley, A McGlothlin… - Intensive care …, 2021 - Springer
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious
disease, with a 90-day mortality of 15%–30%. Despite this, <3000 people have been …
disease, with a 90-day mortality of 15%–30%. Despite this, <3000 people have been …
Effectiveness of casirivimab-imdevimab and sotrovimab during a SARS-CoV-2 Delta variant surge: a cohort study and randomized comparative effectiveness trial
…, S Berry, AM Crawford, A McGlothlin… - JAMA Network …, 2022 - jamanetwork.com
Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…
